Retatrutide: The Triple-Agonist Peptide Redefining Weight Loss Research in 2026

By AtoZ Research Team | February 2026 | 10 min read

The landscape of metabolic research has shifted dramatically with the emergence of retatrutide (LY3437943), the first triple hormone receptor agonist to enter advanced clinical development. Simultaneously targeting GLP-1, GIP, and glucagon receptors, this 39-amino acid peptide has produced the most significant body weight reductions ever observed in clinical trials — up to 24.2% over 48 weeks. For researchers studying obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD), retatrutide represents a paradigm shift in multi-receptor pharmacology.

What Is Retatrutide?

Retatrutide (also known as LY3437943, and informally as "Triple G") is an investigational peptide developed by Eli Lilly and Company. With a molecular weight of approximately 4,986.71 Da and the molecular formula C₂₃₀H₃₅₀N₅₀O₆₉S₂ (CAS: 2381089-83-2), it is a single-molecule tri-agonist designed to activate three distinct incretin and metabolic hormone receptors simultaneously:

• Glucagon-like peptide-1 (GLP-1) receptor — appetite suppression and glucose homeostasis
• Glucose-dependent insulinotropic polypeptide (GIP) receptor — enhanced lipid metabolism and insulin sensitization
• Glucagon receptor — increased energy expenditure and hepatic lipid oxidation

This triple-receptor approach builds upon the dual GLP-1/GIP agonism of tirzepatide (Mounjaro), adding glucagon receptor activation as a third metabolic lever. The result is a compound with the potential for additive — and potentially synergistic — metabolic effects that no single- or dual-agonist has achieved to date ^[1].

Mechanism of Action: How Triple Agonism Works

Understanding why retatrutide has generated such remarkable research data requires examining each receptor pathway and how they interact.

GLP-1 Receptor Agonism

GLP-1 receptor activation is the most well-characterized mechanism in the incretin field, shared by semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda). When retatrutide engages GLP-1 receptors, several downstream effects are observed in research settings:

• Delayed gastric emptying, promoting satiety
• Central nervous system appetite suppression via hypothalamic signaling
• Glucose-dependent insulin secretion from pancreatic beta cells
• Suppression of inappropriate glucagon secretion in hyperglycemic states

This component alone is responsible for meaningful weight loss and glycemic improvements, as demonstrated by the entire class of GLP-1 receptor agonists now widely studied in metabolic research.

GIP Receptor Agonism

The addition of GIP receptor agonism — first validated clinically by tirzepatide — provides complementary metabolic benefits. GIP signaling is involved in:

• Enhanced lipid buffering in adipose tissue, potentially improving metabolic health
• Augmented insulin secretion, working synergistically with GLP-1
• Possible improvements in bone mineral density, a concern with GLP-1-only agents
• Improved tolerability — GIP co-agonism may attenuate the nausea commonly associated with GLP-1 receptor activation

Research by Coskun et al. (2022) in Cell Metabolism first characterized the combined GIP/GLP-1/glucagon receptor agonism of LY3437943 in preclinical models, demonstrating superior weight loss and metabolic improvements compared to dual agonists ^[3].

Glucagon Receptor Agonism: The Differentiating Factor

The glucagon receptor component is what distinguishes retatrutide from every other obesity and diabetes peptide in development. Historically, glucagon has been viewed as counterproductive in metabolic disease due to its hyperglycemic effects. However, emerging research reveals that controlled glucagon receptor activation produces several beneficial outcomes:

• Increased resting energy expenditure — Glucagon stimulates thermogenesis and metabolic rate, meaning the body burns more calories at rest
• Hepatic lipid oxidation — Glucagon drives the liver to mobilize and oxidize stored fat, directly addressing fatty liver disease
• Amino acid metabolism — Glucagon receptor activation increases amino acid catabolism, contributing to overall energy balance
• Appetite modulation — Emerging evidence suggests glucagon may have independent effects on satiety signaling

Crucially, the concurrent GLP-1 and GIP receptor agonism in retatrutide appears to counterbalance the hyperglycemic potential of glucagon receptor activation, creating a metabolic environment where the benefits of all three pathways are preserved while their individual limitations are mitigated ^{[1, 3]}.

Key Clinical Findings: Phase 2 Trial Data

The most compelling evidence for retatrutide comes from two landmark Phase 2 clinical trials published in 2023, which remain the most frequently cited data points in obesity and diabetes research.

Obesity Trial (Jastreboff et al., NEJM 2023)

In this pivotal Phase 2 study published in the New England Journal of Medicine, researchers enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to receive weekly subcutaneous injections of retatrutide at various doses (1, 4, 8, or 12 mg) or placebo over 48 weeks ^[1].

The results were unprecedented:

• 12 mg dose: Mean body weight reduction of 24.2% from baseline at 48 weeks
• 8 mg dose: Mean weight loss of approximately 22.8%
• 4 mg dose: Mean weight loss of approximately 17.5%
• Weight loss trajectory: Notably, the weight loss curves had not yet plateaued at 48 weeks, suggesting further reductions with continued treatment
• ≥5% threshold: 100% of participants on the 12 mg dose achieved at least 5% weight loss
• ≥15% threshold: Over 90% of participants on the 8 mg and 12 mg doses lost 15% or more of body weight

To put this in context, the 24.2% figure exceeds the weight loss observed with semaglutide 2.4 mg (~15-17%) and even tirzepatide at its highest dose (~22.5% at 72 weeks in the SURMOUNT-1 trial). Retatrutide achieved comparable or superior results in a shorter timeframe.

Type 2 Diabetes Trial (Rosenstock et al., Lancet 2023)

A parallel Phase 2 study published in The Lancet evaluated retatrutide in 281 adults with type 2 diabetes. Over 36 weeks, the trial demonstrated ^[2]:

• HbA1c reductions of up to 2.02% from baseline at the highest doses
• Fasting glucose normalization in a significant proportion of participants
• Meaningful weight loss in the diabetes population (typically more resistant to pharmacological weight reduction)
• Favorable lipid profile changes, including reductions in triglycerides

These glycemic improvements are particularly notable because the glucagon receptor agonist component — which would be expected to raise blood glucose in isolation — was effectively counterbalanced by the GLP-1 and GIP components, validating the triple-agonist design principle.

Hepatic Steatosis: A Breakthrough Finding

Perhaps the most striking secondary finding from the Phase 2 program was retatrutide's effect on liver fat. MRI-proton density fat fraction (MRI-PDFF) measurements revealed:

• Near-complete resolution of hepatic steatosis in a significant proportion of subjects on higher doses
• Liver fat reductions far exceeding those seen with GLP-1 receptor agonists alone
• The glucagon receptor component is believed to be the primary driver, promoting hepatic lipid mobilization and beta-oxidation

This has profound implications for MASLD (formerly NAFLD) and metabolic-associated steatohepatitis (MASH/NASH) research, conditions affecting an estimated 25-30% of the global adult population for which no approved pharmacological treatments currently exist.

Safety and Tolerability Profile

As with all investigational compounds, the safety data from Phase 2 trials requires careful evaluation. The most commonly reported adverse events were gastrointestinal in nature:

• Nausea — reported in approximately 25-45% of participants (dose-dependent), generally mild to moderate and diminishing over time
• Diarrhea — reported in approximately 15-25% of participants
• Vomiting — reported in approximately 10-15% of participants
• Decreased appetite — frequently reported but considered a pharmacological effect rather than an adverse event by many researchers

Importantly, the dose-escalation protocol used in the Phase 2 trials demonstrated that gradual titration significantly improved tolerability. The glucagon component did not produce clinically meaningful hyperglycemia when combined with GLP-1/GIP agonism, and cardiovascular safety signals were not identified in the Phase 2 dataset ^{[1, 2]}.

It is worth noting that Phase 2 trials are not powered to detect rare adverse events, and the ongoing Phase 3 program will provide more comprehensive safety data across larger and more diverse populations.

Current Research Status: The TRIUMPH Phase 3 Program

Based on the extraordinary Phase 2 results, Eli Lilly launched the TRIUMPH clinical trial program — a comprehensive Phase 3 initiative evaluating retatrutide across multiple indications:

• TRIUMPH-1: Obesity/overweight without type 2 diabetes
• TRIUMPH-2: Obesity/overweight with type 2 diabetes
• TRIUMPH-3: MASH (metabolic-associated steatohepatitis) with liver fibrosis
• TRIUMPH-4: Obstructive sleep apnea related to obesity

These trials are enrolling thousands of participants globally and are expected to report primary results between 2025 and 2027. The breadth of the TRIUMPH program reflects the potential for retatrutide to address multiple interconnected metabolic conditions — obesity, diabetes, liver disease, and sleep apnea — with a single therapeutic agent.

If Phase 3 results confirm the Phase 2 findings, regulatory submissions could follow in late 2026 or 2027, with potential market availability in 2027-2028.

Retatrutide vs. Other Peptides in the Metabolic Research Landscape

To understand retatrutide's position in the current research landscape, it helps to compare it with other peptides under investigation:

Compound	Receptor Targets	Max Weight Loss (Phase 2/3)	Development Stage
Semaglutide (Wegovy)	GLP-1	~15-17%	Approved
Tirzepatide (Zepbound)	GLP-1 + GIP	~22.5%	Approved
Retatrutide	GLP-1 + GIP + Glucagon	~24.2%	Phase 3
Survodutide	GLP-1 + Glucagon	~19%	Phase 3
CagriSema	GLP-1 + Amylin	~15-17%	Phase 3

The progression from single (GLP-1) to dual (GLP-1/GIP) to triple (GLP-1/GIP/glucagon) agonism represents an evolving understanding that metabolic disease involves multiple interconnected hormonal pathways. Retatrutide's data suggests that engaging all three simultaneously may be the most effective pharmacological approach to obesity and its comorbidities.

Implications for Research: Why Retatrutide Matters

For the research community, retatrutide raises several important questions and opens new avenues of investigation:

1. Metabolic Synergy

The triple-agonist concept validates the hypothesis that multi-receptor engagement produces outcomes greater than the sum of individual agonisms. Understanding the precise molecular mechanisms driving this synergy — particularly the interplay between glucagon's catabolic effects and GLP-1/GIP's anabolic effects on pancreatic islets — is an active area of investigation.

2. Liver Disease Applications

The dramatic liver fat reductions position retatrutide as a leading candidate in MASH/NASH research. The glucagon receptor component's ability to drive hepatic fat oxidation, combined with the overall weight loss effects, may produce histological improvements (fibrosis regression, inflammation resolution) that have eluded other therapeutic approaches.

3. Cardiovascular Outcomes

Given the established cardiovascular benefits of GLP-1 receptor agonists, researchers are keenly interested in whether retatrutide's additional receptor targets amplify cardioprotective effects. The TRIUMPH program includes cardiovascular safety monitoring, but dedicated outcomes trials may follow.

4. Body Composition

A critical question for all weight loss agents is the proportion of lean mass versus fat mass lost. Glucagon's role in amino acid catabolism raises theoretical concerns about muscle loss, though early data suggest that the magnitude of fat mass reduction far outweighs any lean mass changes. This remains an active research question.

Future Outlook: What's Next for Retatrutide Research?

The trajectory for retatrutide research over the next 2-3 years is likely to be defined by several key developments:

• Phase 3 data readouts (2025-2027): The TRIUMPH program will definitively establish efficacy and safety across multiple indications. Primary endpoints for obesity and diabetes arms are anticipated in late 2025 to mid-2026.
• MASH/NASH data: The TRIUMPH-3 liver disease trial could be practice-changing. If retatrutide demonstrates fibrosis regression and MASH resolution, it would enter a therapeutic area with enormous unmet need.
• Combination approaches: Researchers are already exploring whether retatrutide could be combined with other agents — such as amylin analogs or muscle-sparing compounds like bimagrumab — to further optimize metabolic outcomes.
• Long-term durability: Phase 3 trials with longer treatment durations will answer critical questions about weight loss maintenance, metabolic adaptation, and long-term safety.
• Oral formulations: Following the trend established by oral semaglutide, research into oral tri-agonist delivery is an area of pharmaceutical interest.

Key Takeaways for Researchers

• Retatrutide is the first triple-agonist peptide (GLP-1/GIP/glucagon) in advanced clinical development
• Phase 2 data demonstrated 24.2% mean weight loss at 48 weeks — the highest ever reported for a pharmacological agent
• The glucagon receptor component provides unique benefits: increased energy expenditure and near-complete liver fat resolution
• The TRIUMPH Phase 3 program is evaluating retatrutide across obesity, diabetes, MASH, and sleep apnea
• Molecular formula: C₂₃₀H₃₅₀N₅₀O₆₉S₂ | MW: 4,986.71 Da | CAS: 2381089-83-2
• Store lyophilized at -20°C; reconstituted at 2-8°C, use within 30 days

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID: 37385275
2. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X. PMID: 37385278
3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PMID: 36070752
4. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. doi:10.1038/nm.3761. PMID: 25485909
5. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending-dose trial. Lancet. 2022;400(10366):1869-1881. PMID: 36354040

This article is intended for educational and research purposes only. Retatrutide is an investigational compound not approved for human use by the FDA. All references to clinical data describe research findings and do not constitute medical advice. For research use only.